Logo image of CLNN

CLENE INC (CLNN) Stock Fundamental Analysis

NASDAQ:CLNN - Nasdaq - US1856342019 - Common Stock - Currency: USD

3.68  +0.01 (+0.27%)

Fundamental Rating

2

Overall CLNN gets a fundamental rating of 2 out of 10. We evaluated CLNN against 550 industry peers in the Biotechnology industry. CLNN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CLNN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLNN had negative earnings in the past year.
CLNN had a negative operating cash flow in the past year.
In the past 5 years CLNN always reported negative net income.
CLNN had a negative operating cash flow in each of the past 5 years.
CLNN Yearly Net Income VS EBIT VS OCF VS FCFCLNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CLNN has a Return On Assets of -114.84%. This is in the lower half of the industry: CLNN underperforms 79.31% of its industry peers.
Industry RankSector Rank
ROA -114.84%
ROE N/A
ROIC N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLNN Yearly ROA, ROE, ROICCLNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

CLNN's Gross Margin of 78.86% is amongst the best of the industry. CLNN outperforms 84.57% of its industry peers.
CLNN's Gross Margin has improved in the last couple of years.
CLNN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
CLNN Yearly Profit, Operating, Gross MarginsCLNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLNN has been increased compared to 1 year ago.
The number of shares outstanding for CLNN has been increased compared to 5 years ago.
The debt/assets ratio for CLNN is higher compared to a year ago.
CLNN Yearly Shares OutstandingCLNN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLNN Yearly Total Debt VS Total AssetsCLNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -18.43, we must say that CLNN is in the distress zone and has some risk of bankruptcy.
CLNN's Altman-Z score of -18.43 is on the low side compared to the rest of the industry. CLNN is outperformed by 83.30% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.43
ROIC/WACCN/A
WACC12.7%
CLNN Yearly LT Debt VS Equity VS FCFCLNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

CLNN has a Current Ratio of 1.36. This is a normal value and indicates that CLNN is financially healthy and should not expect problems in meeting its short term obligations.
CLNN's Current ratio of 1.36 is on the low side compared to the rest of the industry. CLNN is outperformed by 83.12% of its industry peers.
A Quick Ratio of 1.36 indicates that CLNN should not have too much problems paying its short term obligations.
CLNN has a worse Quick ratio (1.36) than 82.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 1.36
CLNN Yearly Current Assets VS Current LiabilitesCLNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

CLNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.02%, which is quite impressive.
The Revenue for CLNN has decreased by -43.82% in the past year. This is quite bad
Measured over the past years, CLNN shows a very negative growth in Revenue. The Revenue has been decreasing by -21.98% on average per year.
EPS 1Y (TTM)54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
Revenue 1Y (TTM)-43.82%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%10.96%

3.2 Future

The Earnings Per Share is expected to grow by 21.34% on average over the next years. This is a very strong growth
CLNN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 306.69% yearly.
EPS Next Y71.07%
EPS Next 2Y31.84%
EPS Next 3Y33.86%
EPS Next 5Y21.34%
Revenue Next Year-35.41%
Revenue Next 2Y246.01%
Revenue Next 3Y544.01%
Revenue Next 5Y306.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLNN Yearly Revenue VS EstimatesCLNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CLNN Yearly EPS VS EstimatesCLNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNN Price Earnings VS Forward Price EarningsCLNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLNN Per share dataCLNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

CLNN's earnings are expected to grow with 33.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.84%
EPS Next 3Y33.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLENE INC

NASDAQ:CLNN (8/8/2025, 8:26:23 PM)

3.68

+0.01 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners12.55%
Inst Owner Change-20.08%
Ins Owners22.82%
Ins Owner Change-0.04%
Market Cap33.05M
Analysts81.67
Price Target36.43 (889.95%)
Short Float %4.05%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.62%
Min EPS beat(2)-91.95%
Max EPS beat(2)90.71%
EPS beat(4)3
Avg EPS beat(4)9.67%
Min EPS beat(4)-91.95%
Max EPS beat(4)90.71%
EPS beat(8)5
Avg EPS beat(8)-0.74%
EPS beat(12)8
Avg EPS beat(12)14.45%
EPS beat(16)10
Avg EPS beat(16)36.2%
Revenue beat(2)1
Avg Revenue beat(2)4.28%
Min Revenue beat(2)-31.37%
Max Revenue beat(2)39.93%
Revenue beat(4)1
Avg Revenue beat(4)-1.86%
Min Revenue beat(4)-31.37%
Max Revenue beat(4)39.93%
Revenue beat(8)3
Avg Revenue beat(8)9.1%
Revenue beat(12)5
Avg Revenue beat(12)18.17%
Revenue beat(16)8
Avg Revenue beat(16)32.69%
PT rev (1m)0%
PT rev (3m)-20.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.1%
EPS NY rev (1m)0%
EPS NY rev (3m)49.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-27.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 94.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.23
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-2.14
OCFYN/A
SpS0.04
BVpS-0.55
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -114.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.86%
FCFM N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.25%
Cap/Sales 1.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.36
Quick Ratio 1.36
Altman-Z -18.43
F-Score4
WACC12.7%
ROIC/WACCN/A
Cap/Depr(3y)176.04%
Cap/Depr(5y)141.46%
Cap/Sales(3y)385.66%
Cap/Sales(5y)305.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
EPS Next Y71.07%
EPS Next 2Y31.84%
EPS Next 3Y33.86%
EPS Next 5Y21.34%
Revenue 1Y (TTM)-43.82%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%10.96%
Revenue Next Year-35.41%
Revenue Next 2Y246.01%
Revenue Next 3Y544.01%
Revenue Next 5Y306.69%
EBIT growth 1Y28.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.03%
EBIT Next 3Y49.72%
EBIT Next 5Y64.33%
FCF growth 1Y51.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.22%
OCF growth 3YN/A
OCF growth 5YN/A